FDMT News

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?

4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks | 3 weeks ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seekingalpha | 1 month ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seekingalpha | 1 month ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seekingalpha | 1 month ago

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic macular edema.

Marketbeat | 2 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seekingalpha | 2 months ago

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.86 per share a year ago.

Zacks | 2 months ago

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $0.53 per share. This compares to a loss of $0.9 per share a year ago.

Zacks | 4 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seekingalpha | 4 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Seekingalpha | 4 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 6 months ago

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

Seekingalpha | 7 months ago